Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 7, Issue 6, 2019, Pages 429-441

  Pollock, Carol ^a   Stefánsson, Bergur ^b   Reyner, Daniel ^c   Rossing, Peter ^d,e   Sjöström, C David ^b   Wheeler, David C ^f   Langkilde, Anna Maria ^b   Heerspink, Hiddo J L ^g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d STENO DIABETES CENTER   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; BENZHYDRYL DERIVATIVE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSIDE;

ADULT; ALBUMINURIA; ARTICLE; AUSTRALIA; CANADA; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEXICO; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AFRICA; SOUTH KOREA; SPAIN; TAIWAN; UNITED STATES; URINARY TRACT INFECTION; AGED; COMPLICATION; DIABETIC NEPHROPATHY; MIDDLE AGED; PHARMACOLOGY; URINE;

ADAMANTANE; AGED; ALBUMINURIA; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85065609449     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(19)30086-5     Document Type: Article

References (34)

1. Coutinho, M, Gerstein, HC, Wang, Y, Yusuf, S, The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12·4 years. Diabetes Care 22 (1999), 233–240.
2. Fox, CS, Matsushita, K, Woodward, M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380 (2013), 1662–1673.
3. Perkovic, V, Heerspink, HL, Chalmers, J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 (2013), 517–523.
4. Zoungas, S, Arima, H, Gerstein, HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5 (2017), 431–437.
5. Heerspink, HJ, Greene, T, Tighiouart, H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol 7 (2019), 128–139.
6. Heerspink, HJ, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZ, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation 134 (2016), 752–772.
7. Muskiet, MHA, Tonneijck, L, Smits, MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13 (2017), 605–628.
8. Petrykiv, S, Sjostrom, CD, Greasley, PJ, Xu, J, Persson, F, Heerspink, HJL, Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12 (2017), 751–759.
9. Dekkers, CCJ, Wheeler, DC, Sjöström, CD, Stefansson, BV, Cain, V, Heerspink, HJL, Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b–4 chronic kidney disease. Nephrol Dial Transplant 33 (2018), 2005–2011.
10. Perkovic, V, de Zeeuw, D, Mahaffey, KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
11. Fioretto, P, Stefansson, BV, Johnsson, E, Cain, VA, Sjostrom, CD, Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59 (2016), 2036–2039.
12. Cherney, DZI, Zinman, B, Inzucchi, SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
13. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
14. Heerspink, HJ, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
15. Heerspink, HJ, Johnsson, E, Gause-Nilsson, I, Cain, VA, Sjöström, CD, Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
16. Mosenzon, O, Leibowitz, G, Bhatt, DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40 (2017), 69–76.
17. Rosenstock, J, Perkovic, V, Johansen, OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321 (2019), 69–79.
18. Groop, P-H, Cooper, ME, Perkovic, V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 19 (2017), 1610–1619.
19. Levey, AS, Coresh, J, Greene, T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007), 766–772.
20. Matsuo, S, Imai, E, Horio, M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 (2009), 982–992.
21. Chen, LI, Guh, JY, Wu, KD, et al. Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults. PLoS One, 9, 2014, e99645.
22. Men, P, Li, XT, Tang, HL, Zhai, SD, Efficacy and safety of saxagliptin in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One, 13, 2018, e0197321.
23. Ptaszynska, A, Johnsson, KM, Parikh, SJ, de Bruin, TW, Apanovitch, AM, List, JF, Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf 37 (2014), 815–829.
24. Rosenstock, J, Hansen, L, Zee, P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
25. Mathieu, C, Ranetti, AE, Li, D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 38 (2015), 2009–2017.
26. Heerspink, HJ, Ninomiya, T, Persson, F, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 18 (2016), 169–177.
27. de Zeeuw, D, Remuzzi, G, Parving, HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004), 2309–2320.
28. Panchapakesan, U, Pegg, K, Gross, S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?. PLoS One, 8, 2013, e54442.
29. Esterline, RL, Vaag, A, Oscarsson, J, Vora, J, Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?. Eur J Endocrinol 178 (2018), R113–R125.
30. Gilbert, RE, SGLT2 inhibitors: β blockers for the kidney?. Lancet Diabetes Endocrinol, 4, 2016, 814.
31. Kohan, DE, Fioretto, P, Tang, W, List, JF, Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
32. Fioretto, P, Del Prato, S, Buse, JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab 20 (2018), 2532–2540.
33. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
34. Jabbour, S, Seufert, J, Scheen, A, Bailey, CJ, Karup, C, Langkilde, AM, Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20 (2018), 620–628.